PharmaLegacy
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A preclinical pharmacology CRO providing validated animal models and testing services for oncology, immunology, and metabolic disease drug development.
OncologyImmunologyMetabolic DiseaseCentral Nervous SystemOphthalmologyInfectious DiseasesCardiovascularPulmonologyOrthopedicsOtologyPain
Technology Platform
Comprehensive preclinical pharmacology platform featuring over 1,500 validated animal models across 100+ indications, supported by in vitro assay systems including kinase/enzyme assays, BaF3 assays, GPCR assays, and specialized cell-based assays.
Opportunities
Growth opportunities include expanding service offerings in high-demand areas like immuno-oncology and cell/gene therapy support, leveraging China's growing biopharma sector, and further geographic expansion through additional partnerships or acquisitions.
Risk Factors
Key risks include dependence on client project flow, intense competition from larger global CROs, regulatory changes affecting preclinical research standards, and potential disruptions to animal model supply chains.
Competitive Landscape
Competes with global preclinical CROs like Charles River Laboratories, Labcorp, and WuXi AppTec, differentiating through specialized pharmacology focus, rapid study initiation, and extensive validated model portfolio particularly in complex humanized systems.